Insulin Degludec/ Liraglutide Biosimilar (Chia Tai Tianqing)

Primary objective: To evaluate the similarity of the pharmacokinetic (PK) characteristics of the single-dose test formulation of insulin degludec liraglutide injection (TQF3517 injection) and the reference formulation of insulin degludec liraglutide injection (Viovac®) in healthy adult subjects. Secondary objectives: To evaluate the safety of the test formulation TQF3517 injection and the reference formulation Viovac® in healthy subjects; To evaluate the immunogenicity of the test formulation TQF3517 injection and the reference formulation Viovac® in healthy subjects.